Loading…
Neoadjuvant therapy for breast cancer treatment: an expert panel recommendation from the Brazilian Society of Breast Surgeons 2018
Purpose Breast cancer neoadjuvant chemotherapy (NAC) consists of the administration of cytotoxic and targeted drugs prior to breast surgery, with the objective of reducing the tumor burden to allow breast conservation. NAC also aims to improve long-term treatment outcomes such as disease-free and ov...
Saved in:
| Published in: | Breast cancer research and treatment 2018-11, Vol.172 (2), p.265-272 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c470t-d3de93c2c52103e52e24952f120c1773bdc82a78d97c34d41d00b881b17ada913 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c470t-d3de93c2c52103e52e24952f120c1773bdc82a78d97c34d41d00b881b17ada913 |
| container_end_page | 272 |
| container_issue | 2 |
| container_start_page | 265 |
| container_title | Breast cancer research and treatment |
| container_volume | 172 |
| creator | Barbosa C Rocha, Fernanda Falcone, Ana Beatriz Buzaid, Antonio Carlos Pimenta, Juliana Martins Schvartsman, Gustavo Frasson, Antonio Luiz |
| description | Purpose
Breast cancer neoadjuvant chemotherapy (NAC) consists of the administration of cytotoxic and targeted drugs prior to breast surgery, with the objective of reducing the tumor burden to allow breast conservation. NAC also aims to improve long-term treatment outcomes such as disease-free and overall survival. To optimize clinical practice with the best available evidence for breast cancer patients in the setting of neoadjuvant treatment, the Brazilian Society of Breast Surgeons (Sociedade Brasileira de Mastologia—SBM) held a consensus conference to develop this guideline.
Methods
Twenty-two questions addressing relevant breast cancer neoadjuvant treatment were previously formulated. The voting panel comprised 25 specialists from the SBM. A consensus was established if there was 75% agreement. If there was less concordance, after discussion, the consensus was determined by a 51% concordance.
Results
The recommendations were based on the best level of scientific evidence and the opinion from breast cancer experts, when no such research data were available.
Conclusion
This manuscript provides updated guidance according to the views of the SBM’s experts for the clinical practice of breast cancer surgeons. This manuscript depicts the summarized recommendations for NAC treatment. |
| doi_str_mv | 10.1007/s10549-018-4912-x |
| format | article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2087996517</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A558584330</galeid><sourcerecordid>A558584330</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-d3de93c2c52103e52e24952f120c1773bdc82a78d97c34d41d00b881b17ada913</originalsourceid><addsrcrecordid>eNp1kk1v1DAQhi0EokvhB3BBlpAQlxR_xHHMrVR8SRUcCmfLsSe7WSX2YjtolyO_HIctlCKQD7ZnnvfVzGgQekzJGSVEvkiUiFpVhLZVrSir9nfQigrJK8movItWhDayalrSnKAHKW0JIUoSdR-d8PJSDecr9P0DBOO281fjM84biGZ3wH2IuItgUsbWeAsR5_LLE_j8EhuPYb-DmPHOeBhxBBumknImD8HjPoZpMcKvovk2jEPBr4IdIB9w6Evwp-vVHNcQfMKs1P4Q3evNmODR9X2KPr95_eniXXX58e37i_PLytaS5MpxB4pbZgWjhINgwGolWE8ZsVRK3jnbMiNbp6TltaupI6RrW9pRaZxRlJ-i50ffXQxfZkhZT0OyMI6ljTAnzUgry1QElQV9-he6DXP0pbqFahThQogbam1G0IPvQ47GLqb6XIhWtDXnpFBn_6DKcTANNnjohxK_JXj2h2ADZsybFMZ5GW-6DdIjaGNIKUKvd3GYTDxoSvSyIPq4ILoMWS8LovdF8-S6s7mbwP1W_NqIArAjkErKryHetP5_1x95qsRD</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2086903555</pqid></control><display><type>article</type><title>Neoadjuvant therapy for breast cancer treatment: an expert panel recommendation from the Brazilian Society of Breast Surgeons 2018</title><source>Springer Nature</source><creator>Barbosa C Rocha, Fernanda ; Falcone, Ana Beatriz ; Buzaid, Antonio Carlos ; Pimenta, Juliana Martins ; Schvartsman, Gustavo ; Frasson, Antonio Luiz</creator><creatorcontrib>Barbosa C Rocha, Fernanda ; Falcone, Ana Beatriz ; Buzaid, Antonio Carlos ; Pimenta, Juliana Martins ; Schvartsman, Gustavo ; Frasson, Antonio Luiz</creatorcontrib><description>Purpose
Breast cancer neoadjuvant chemotherapy (NAC) consists of the administration of cytotoxic and targeted drugs prior to breast surgery, with the objective of reducing the tumor burden to allow breast conservation. NAC also aims to improve long-term treatment outcomes such as disease-free and overall survival. To optimize clinical practice with the best available evidence for breast cancer patients in the setting of neoadjuvant treatment, the Brazilian Society of Breast Surgeons (Sociedade Brasileira de Mastologia—SBM) held a consensus conference to develop this guideline.
Methods
Twenty-two questions addressing relevant breast cancer neoadjuvant treatment were previously formulated. The voting panel comprised 25 specialists from the SBM. A consensus was established if there was 75% agreement. If there was less concordance, after discussion, the consensus was determined by a 51% concordance.
Results
The recommendations were based on the best level of scientific evidence and the opinion from breast cancer experts, when no such research data were available.
Conclusion
This manuscript provides updated guidance according to the views of the SBM’s experts for the clinical practice of breast cancer surgeons. This manuscript depicts the summarized recommendations for NAC treatment.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-018-4912-x</identifier><identifier>PMID: 30099633</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Adjuvant chemotherapy ; Brazil - epidemiology ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - epidemiology ; Breast Neoplasms - pathology ; Breast Neoplasms - surgery ; Breast surgery ; Cancer research ; Cancer therapies ; Chemotherapy ; Clinical medicine ; Cytotoxicity ; Drug therapy ; Evidence-based medicine ; Female ; Health aspects ; Humans ; Mastectomy ; Medical societies ; Medicine ; Medicine & Public Health ; Neoadjuvant Therapy ; Oncology ; Physicians ; Review ; Surgeons ; Surgery</subject><ispartof>Breast cancer research and treatment, 2018-11, Vol.172 (2), p.265-272</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2018</rights><rights>COPYRIGHT 2018 Springer</rights><rights>Breast Cancer Research and Treatment is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-d3de93c2c52103e52e24952f120c1773bdc82a78d97c34d41d00b881b17ada913</citedby><cites>FETCH-LOGICAL-c470t-d3de93c2c52103e52e24952f120c1773bdc82a78d97c34d41d00b881b17ada913</cites><orcidid>0000-0002-6725-1993</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30099633$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Barbosa C Rocha, Fernanda</creatorcontrib><creatorcontrib>Falcone, Ana Beatriz</creatorcontrib><creatorcontrib>Buzaid, Antonio Carlos</creatorcontrib><creatorcontrib>Pimenta, Juliana Martins</creatorcontrib><creatorcontrib>Schvartsman, Gustavo</creatorcontrib><creatorcontrib>Frasson, Antonio Luiz</creatorcontrib><title>Neoadjuvant therapy for breast cancer treatment: an expert panel recommendation from the Brazilian Society of Breast Surgeons 2018</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>Purpose
Breast cancer neoadjuvant chemotherapy (NAC) consists of the administration of cytotoxic and targeted drugs prior to breast surgery, with the objective of reducing the tumor burden to allow breast conservation. NAC also aims to improve long-term treatment outcomes such as disease-free and overall survival. To optimize clinical practice with the best available evidence for breast cancer patients in the setting of neoadjuvant treatment, the Brazilian Society of Breast Surgeons (Sociedade Brasileira de Mastologia—SBM) held a consensus conference to develop this guideline.
Methods
Twenty-two questions addressing relevant breast cancer neoadjuvant treatment were previously formulated. The voting panel comprised 25 specialists from the SBM. A consensus was established if there was 75% agreement. If there was less concordance, after discussion, the consensus was determined by a 51% concordance.
Results
The recommendations were based on the best level of scientific evidence and the opinion from breast cancer experts, when no such research data were available.
Conclusion
This manuscript provides updated guidance according to the views of the SBM’s experts for the clinical practice of breast cancer surgeons. This manuscript depicts the summarized recommendations for NAC treatment.</description><subject>Adjuvant chemotherapy</subject><subject>Brazil - epidemiology</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - epidemiology</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - surgery</subject><subject>Breast surgery</subject><subject>Cancer research</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Clinical medicine</subject><subject>Cytotoxicity</subject><subject>Drug therapy</subject><subject>Evidence-based medicine</subject><subject>Female</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Mastectomy</subject><subject>Medical societies</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neoadjuvant Therapy</subject><subject>Oncology</subject><subject>Physicians</subject><subject>Review</subject><subject>Surgeons</subject><subject>Surgery</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kk1v1DAQhi0EokvhB3BBlpAQlxR_xHHMrVR8SRUcCmfLsSe7WSX2YjtolyO_HIctlCKQD7ZnnvfVzGgQekzJGSVEvkiUiFpVhLZVrSir9nfQigrJK8movItWhDayalrSnKAHKW0JIUoSdR-d8PJSDecr9P0DBOO281fjM84biGZ3wH2IuItgUsbWeAsR5_LLE_j8EhuPYb-DmPHOeBhxBBumknImD8HjPoZpMcKvovk2jEPBr4IdIB9w6Evwp-vVHNcQfMKs1P4Q3evNmODR9X2KPr95_eniXXX58e37i_PLytaS5MpxB4pbZgWjhINgwGolWE8ZsVRK3jnbMiNbp6TltaupI6RrW9pRaZxRlJ-i50ffXQxfZkhZT0OyMI6ljTAnzUgry1QElQV9-he6DXP0pbqFahThQogbam1G0IPvQ47GLqb6XIhWtDXnpFBn_6DKcTANNnjohxK_JXj2h2ADZsybFMZ5GW-6DdIjaGNIKUKvd3GYTDxoSvSyIPq4ILoMWS8LovdF8-S6s7mbwP1W_NqIArAjkErKryHetP5_1x95qsRD</recordid><startdate>20181101</startdate><enddate>20181101</enddate><creator>Barbosa C Rocha, Fernanda</creator><creator>Falcone, Ana Beatriz</creator><creator>Buzaid, Antonio Carlos</creator><creator>Pimenta, Juliana Martins</creator><creator>Schvartsman, Gustavo</creator><creator>Frasson, Antonio Luiz</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6725-1993</orcidid></search><sort><creationdate>20181101</creationdate><title>Neoadjuvant therapy for breast cancer treatment: an expert panel recommendation from the Brazilian Society of Breast Surgeons 2018</title><author>Barbosa C Rocha, Fernanda ; Falcone, Ana Beatriz ; Buzaid, Antonio Carlos ; Pimenta, Juliana Martins ; Schvartsman, Gustavo ; Frasson, Antonio Luiz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-d3de93c2c52103e52e24952f120c1773bdc82a78d97c34d41d00b881b17ada913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adjuvant chemotherapy</topic><topic>Brazil - epidemiology</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - epidemiology</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - surgery</topic><topic>Breast surgery</topic><topic>Cancer research</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Clinical medicine</topic><topic>Cytotoxicity</topic><topic>Drug therapy</topic><topic>Evidence-based medicine</topic><topic>Female</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Mastectomy</topic><topic>Medical societies</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neoadjuvant Therapy</topic><topic>Oncology</topic><topic>Physicians</topic><topic>Review</topic><topic>Surgeons</topic><topic>Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Barbosa C Rocha, Fernanda</creatorcontrib><creatorcontrib>Falcone, Ana Beatriz</creatorcontrib><creatorcontrib>Buzaid, Antonio Carlos</creatorcontrib><creatorcontrib>Pimenta, Juliana Martins</creatorcontrib><creatorcontrib>Schvartsman, Gustavo</creatorcontrib><creatorcontrib>Frasson, Antonio Luiz</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest_Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Barbosa C Rocha, Fernanda</au><au>Falcone, Ana Beatriz</au><au>Buzaid, Antonio Carlos</au><au>Pimenta, Juliana Martins</au><au>Schvartsman, Gustavo</au><au>Frasson, Antonio Luiz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neoadjuvant therapy for breast cancer treatment: an expert panel recommendation from the Brazilian Society of Breast Surgeons 2018</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2018-11-01</date><risdate>2018</risdate><volume>172</volume><issue>2</issue><spage>265</spage><epage>272</epage><pages>265-272</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><abstract>Purpose
Breast cancer neoadjuvant chemotherapy (NAC) consists of the administration of cytotoxic and targeted drugs prior to breast surgery, with the objective of reducing the tumor burden to allow breast conservation. NAC also aims to improve long-term treatment outcomes such as disease-free and overall survival. To optimize clinical practice with the best available evidence for breast cancer patients in the setting of neoadjuvant treatment, the Brazilian Society of Breast Surgeons (Sociedade Brasileira de Mastologia—SBM) held a consensus conference to develop this guideline.
Methods
Twenty-two questions addressing relevant breast cancer neoadjuvant treatment were previously formulated. The voting panel comprised 25 specialists from the SBM. A consensus was established if there was 75% agreement. If there was less concordance, after discussion, the consensus was determined by a 51% concordance.
Results
The recommendations were based on the best level of scientific evidence and the opinion from breast cancer experts, when no such research data were available.
Conclusion
This manuscript provides updated guidance according to the views of the SBM’s experts for the clinical practice of breast cancer surgeons. This manuscript depicts the summarized recommendations for NAC treatment.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>30099633</pmid><doi>10.1007/s10549-018-4912-x</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-6725-1993</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 2018-11, Vol.172 (2), p.265-272 |
| issn | 0167-6806 1573-7217 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2087996517 |
| source | Springer Nature |
| subjects | Adjuvant chemotherapy Brazil - epidemiology Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - epidemiology Breast Neoplasms - pathology Breast Neoplasms - surgery Breast surgery Cancer research Cancer therapies Chemotherapy Clinical medicine Cytotoxicity Drug therapy Evidence-based medicine Female Health aspects Humans Mastectomy Medical societies Medicine Medicine & Public Health Neoadjuvant Therapy Oncology Physicians Review Surgeons Surgery |
| title | Neoadjuvant therapy for breast cancer treatment: an expert panel recommendation from the Brazilian Society of Breast Surgeons 2018 |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T10%3A57%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neoadjuvant%20therapy%20for%20breast%20cancer%20treatment:%20an%20expert%20panel%20recommendation%20from%20the%20Brazilian%20Society%20of%20Breast%20Surgeons%202018&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Barbosa%20C%20Rocha,%20Fernanda&rft.date=2018-11-01&rft.volume=172&rft.issue=2&rft.spage=265&rft.epage=272&rft.pages=265-272&rft.issn=0167-6806&rft.eissn=1573-7217&rft_id=info:doi/10.1007/s10549-018-4912-x&rft_dat=%3Cgale_proqu%3EA558584330%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c470t-d3de93c2c52103e52e24952f120c1773bdc82a78d97c34d41d00b881b17ada913%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2086903555&rft_id=info:pmid/30099633&rft_galeid=A558584330&rfr_iscdi=true |